E2F4: A Drug Target / Disease Biomarker (G1874)

Target Name: E2F4

NCBI ID: G1874

E2F4

E2F4: A Drug Target / Disease Biomarker

E2F4, also known as enterovirus 229E (EV229E), is a member of the Sendai virus family, which includes several plant and animal viruses that cause a range of respiratory diseases. E2F4 is highly infectious and can cause serious disease in humans, particularly in immunosuppressed individuals.

The E2F4 virus has a unique structure, with a genome that is composed of a single open-circle RNA molecule. It has a segmented replication system, with the genome being transcribed into several non-overlapping RNA molecules, which are then translated into proteins. E2F4 also has a unique mechanism of infection, with the virus using a type of immune evasion strategy to infect host cells.

One of the key features of E2F4 is its ability to infect a wide range of cell types, including both epithelial and endothelial cells. This is important for the virus's ability to cause a range of different respiratory diseases, including acute and chronic respiratory distress syndrome (ARDS), a common complication in hospitalized patients.

In addition to its ability to infect a wide range of cell types, E2F4 is also known for its ability to cause a range of different types of respiratory failure. The virus has been shown to cause both acute and chronic respiratory failure in animal models, and has been linked to a number of serious health consequences, including death.

Despite the serious health consequences associated with E2F4, the virus is still being actively studied as a potential drug target. The virus's unique structure and mechanism of infection make it an attractive target for drug development, with researchers currently working to develop small molecules and other compounds that can inhibit the virus's replication.

In addition to its potential as a drug target, E2F4 is also being investigated as a biomarker for a range of respiratory diseases. The virus has been shown to be present in the airways of hospitalized patients with ARDS, and has been used as a marker for the severity of this complication. In addition, the virus has also been used as a marker for other types of respiratory failure, such as acute lung injury (ALI) and acute respiratory distress syndrome (ARDS).

Overall, E2F4 is a highly infectious and serious virus that has the potential to cause a range of different respiratory diseases. Its unique structure and mechanism of infection make it an attractive target for drug development, as well as a potential biomarker for a range of respiratory diseases. Further research is needed to better understand the virus's biology and to develop effective treatments.

Protein Name: E2F Transcription Factor 4

Functions: Transcription activator that binds DNA cooperatively with DP proteins through the E2 recognition site, 5'-TTTC[CG]CGC-3' found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. The DRTF1/E2F complex functions in the control of cell-cycle progression from G1 to S phase. E2F4 binds with high affinity to RBL1 and RBL2. In some instances can also bind RB1. Specifically required for multiciliate cell differentiation: together with MCIDAS and E2F5, binds and activate genes required for centriole biogenesis

The "E2F4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about E2F4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets